Key result
Stanozolol treatment in a patient with congenital protein-C deficiency increased protein C levels but was complicated by a transient ischemic attack at 8 weeks.
Why the study?
Does stanozolol increase circulating levels of protein C in a patient with congenital protein-C deficiency?
Does stanozolol increase circulating levels of protein C in a patient with congenital protein-C deficiency?
While stanozolol successfully increased protein C levels in a patient with congenital deficiency, its use was complicated by a transient ischemic attack.
Answers are grounded in this paper and cite their sources.
Highlights thrombotic risk despite protein C rise; leaves open therapeutic role pending controlled data.
A patient with congenital protein-C deficiency was treated with stanozolol for 8 weeks to increase circulating levels of protein C. A rise in protein C was achieved, accompanied by an increase in factor II, factor X, antithrombin III, and protein S; but at the 8th week the patient suffered a transient ischemia attack.
No takes yet. Share an insight, caveat, or question.
Stefano et al. (1988) studied this question. Stanozolol treatment in a patient with congenital protein-C deficiency increased protein C levels but was complicated by a transient ischemic attack at 8 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: